Protagenic Therapeutics, Inc.\new Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, new issues for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, new issues for the quarter ending 2025-06-30 was $395.47K, a 788.09% increase year-over-year.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, new issues for fiscal 2026 was $395.47K.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, new issues for fiscal 2024 was $1.96M.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, new issues for fiscal 2016 was $4.76M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $395.47K 10-K · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | $497.99K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-26 | |
| 2025-06-30 | $395.47K 10-Q · filed 2026-08-19 | |
| 2025-03-31 | $102.52K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $1.96M 10-K · filed 2025-03-31 | |
| 2024-09-30 | $316.96K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $44.53K 10-Q · filed 2024-11-14 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $4.76M 10-K · filed 2018-04-02 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-17 | |
| 2016-06-30 | $505.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | |
| 2016-03-31 | $4.26M 10-Q · filed 2016-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |